Discover how multi-payload ADCs enhance cancer therapy by combining diverse cytotoxic agents, improving efficacy, overcoming resistance, and expanding therapeutic potential.

Antibody-drug conjugates (ADCs) are made up of a monoclonal antibody linked to a cytotoxic drug (payload) through a stable chemical linker, enabling targeted delivery of the drug to specific cancer cells. The ideal ADC payload should have sufficient toxicity, low immunogenicity, high stability, and

ADCs for ES-SCLC. Image credit: DOI: 10.3390/genes15060701Extensive-stage small-cell lung cancer (ES-SCLC) is a particularly aggressive form of lung cancer characterized by rapid growth and early metastasis. Antibody drugs, especially immune checkpoint inhibitors, have emerged as a promising treatme

Discover cancer immunotherapy techniques like monoclonal antibodies, checkpoint inhibitors, & ADCs. Learn how targeted delivery & tumor selectivity improve cancer treatment.

The 20th Annual PEGS Boston Summit 2024 was held in Boston, MA from May 13-17. During the event, industry experts from across the world gathered to share the latest research in advancements in drug development, protein and antibody engineering, immunotherapy, immunogenicity, expression platforms, mu

Highlights from CAS 2024: advancements in cancer immunotherapy, Alzheimer’s therapies, protein bioinformatics, & novel antibody engineering technologies.

Explore how bispecific antibody-drug conjugates (bsADCs) combine dual-targeting antibodies with cytotoxic payloads, advancing cancer treatment with enhanced precision.

​The AACR Annual Meeting 2024 was held in San Diego, CA from April 5-10, and featured the latest advancements in cancer research, with hundreds of poster presentations, lectures, and exhibits. Scientists, health care professionals, and industry experts from around the world gathered to share innovations and trends in oncology, including: Advances in Diagnostics and Therapeutics...

Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently.

Here at the AACR Annual Meeting 2024, there are over 7000 abstracts, 300 poster presentations, and 50 symposia all about cancer research. A few topics that are currently trending in the conference include cancer vaccines, AI for diagnostics, novel immunotherapies, and antibody-drug conjugates (ADCs) as a new modality.

Explore bispecific antibodies: dual-antigen targeting, IgG-like & non-IgG-like formats, innovative design techniques, & transformative applications in cancer immunotherapy.

Image credit: DOI: 10.3390/cancers16040800 In recent decades, the landscape of therapeutic antibodies has undergone a rapid evolution, catalyzing breakthroughs in modern medicine. These antibodies, characterized by their precise targeting and minimal side effects

Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow, which can cause bone damage, anemia, kidney dysfunction, and weakened immunity. Despite being incurable, advances in antibody therapies have shown significant progress in the management of the disease, highlighting the ongoing efforts in the development of more effective treatments.

Discover how antibodies revolutionize immunotherapy by targeting cancer cells, triggering immune responses, and advancing treatments for cancer and other diseases.

The last few decades have witnessed an acceleration in the discovery and development of therapeutic antibodies.